GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Total Debt per Share

GYRE (Gyre Therapeutics) Total Debt per Share : $0.02 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Total Debt per Share?

$0.02 (As of Dec. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Gyre Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2024 was $0.02.

Gyre Therapeutics Total Debt per Share Historical Data

The historical data trend for Gyre Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Total Debt per Share Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Total Debt per Share
0.02 0.01 0.01 0.02

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.01 - 0.02 0.02 0.02

Gyre Therapeutics Total Debt per Share Calculation

Gyre Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.9+0.7)/86.3
=0.02

Gyre Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.9+0.7)/86.3
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Total Debt per Share
Comparable Companies
PHVS XERS ZYME RCUS NTLA DAWN RCKT REPL CMRX XNCR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
L9S:Germany
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Website
https://www.gyretx.com
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.